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NFκBTumor necrosis factor-like weak inducer of apoptosis (TWEAK) regulates apoptosis, proliferation and inﬂam-
mation in renal epithelial cells and plays a role in acute kidney injury. However, there is little information on
the chronic effects of TWEAK. We hypothesized that TWEAK may inﬂuence renal ﬁbrosis and regulate kidney
ﬁbroblast biology, in part, through Ras pathway.
We studied a chronic model of experimental unilateral ureteral obstruction in wild type and TWEAK deﬁcient
mice, and a murine model of systemic TWEAK overexpression. TWEAK actions were also explored in cultured
renal and embryonic ﬁbroblasts.
TWEAK and TWEAK receptor expression was increased in the obstructed kidneys. The absence of TWEAK de-
creased early kidney tubular damage, inﬂammatory inﬁltrates and myoﬁbroblast number. TWEAK deﬁcient
mice had decreased renal ﬁbrosis 21 days after obstruction, as assessed by extracellular matrix staining. In
mice without prior underlying kidney disease, systemic overexpression of TWEAK induced kidney inﬂamma-
tion and ﬁbrosis. In cultured ﬁbroblasts, TWEAK induced proliferation through activation of the Ras/ERK
pathway. TWEAK also activated nuclear factor κB (NFκB)-dependent inﬂammatory chemokine production
in murine renal ﬁbroblasts.
In conclusion, lack of TWEAK reduces renal ﬁbrosis in a model of persistent kidney insult and overexpression
of TWEAK led to renal ﬁbrosis. TWEAK actions on renal ﬁbroblasts may contribute to the in vivo observations,
as TWEAK promotes inﬂammatory activity and proliferation in ﬁbroblast cultures.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Tissue injury results in signals that trigger inﬂammation, which
contributes to the repair process. If repair fails or the initial kidney
insult persists, interstitial ﬁbrosis ensues [1–3]. Indeed, recovery
from acute kidney injuries (AKI) may evolve to residual interstitialción Jiménez Díaz, Av. Reyes
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l rights reserved.ﬁbrosis [4,5]. In chronic kidney disease (CKD), the degree of interstitial
ﬁbrosis correlates well with outcomes [6–9]. Thus, an improved under-
standing of the molecular and cellular mechanisms promoting kidney
ﬁbrosis may help design novel therapeutic strategies. Irreversible uni-
lateral ureteral obstruction (UUO) is a widely used animal model to
study the mechanisms of non-toxin and non-immune renal injury and
ﬁbrosis [10]. In this model the cause of kidney injury is maintained
throughout the study, thus differing from models of self-limited AKI
such as transient ischemia–reperfusion. Following ureteral obstruction
kidneys develop the main features of CKD, such as tubular cell death,
inﬂammation and ﬁbrosis, in an accelerated fashion.
Renal interstitial ﬁbrosis is characterized by ECM accumulation
and an increased number of activated ﬁbroblasts [11]. Fibroblast
number closely correlates with the severity of tubulointerstitial ﬁbro-
sis and renal disease progression [12].
AC
B
Fig. 1. TWEAK and Fn14 expressions inUUOkidneys. A) Fn14 (all groups ofmice) and B) TWEAK (WTmice only) gene expressions are increased in the obstructed kidney. *p b 0.05 obstructed
vs. Sham. C) Fn14 protein level is also increased in the WT obstructed kidneys. Representative Western blot and quantiﬁcation normalized for alpha-tubulin. *p b 0.05 obstructed vs. Sham.
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to renal injury [13] and may promote renal ﬁbroblast apoptosis
[14]. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK,Sham 2 d. 
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Fig. 3. Inﬂammatory inﬁltrates in the obstructed kidneys are reduced in TWEAK knockout mouse. F4/80 positive macrophages (A) and CD3 positive interstitial lymphocytes (B)
increase in a time-dependent manner after ureter obstruction. The number of macrophages is lower at all time-points in kidneys from TWEAK KO mice, whereas a lower number
of CD3 cells in TWEAK KOmice is only observed up to 14 days after obstruction. Magniﬁcation ×200, scale bar 100 μm. *p b 0.05 vs. Sham. #p b 0.05 TWEAK KO obstructed vs. WT.
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TWEAK receptor, ﬁbroblast growth factor-inducible 14 (Fn14) [18].
Both TWEAK and Fn14 are present in the healthy adult kidney and
their expression increases in experimental AKI [19–21]. In tubular
cells TWEAK induces proliferation, activates nuclear factor κB (NFκB)
and promotes the synthesis of inﬂammatorymediators [21,22]. In addi-
tion, TWEAK induces tubular cell apoptosis in the presence of an in-
ﬂammatory milieu [20]. TWEAK regulates some ECM-related proteins,
namely matrix metalloproteinases (MMPs) and tissue inhibitors of
MMP (TIMPs) in other organ systems [17,23–26] but there is no
information on the role of TWEAK and its receptor in renal ﬁbroblasts.
Increased leukocyte and urinary TWEAK levels and correlation
with renal disease activity in human lupus nephritis, a disease charac-
terized by renal scarring if untreated, suggest that TWEAK may con-
tribute to kidney ﬁbrosis [27,28]. Studies on the effects of TWEAK
on kidney ﬁbrosis are relevant for clinical practice since the ﬁrst
human disease in which neutralizing anti-TWEAK antibodies are
being evaluated in an ongoing clinical trial is a kidney disease, lupus
nephritis [29]. In order to dissect the effect of TWEAK on kidney ﬁbro-
sis, we have addressed the hypothesis that chronic exposure to
TWEAK contributes to kidney ﬁbrosis in a non-autoimmune model
of persistent kidney injury.We now report that UUO kidneys from TWEAK knockout (KO)
mice show decreased myoﬁbroblast number and proliferation, and
reduced ECM deposition when compared to UUO kidneys from wild
type (WT) mice. Conversely, mice without underlying kidney injury
developed kidney ﬁbrosis following systemic TWEAK overexpression.
TWEAK direct actions on cultured renal interstitial ﬁbroblasts may
underlie the in vivo observations.
2. Material and methods
2.1. Cell lines
TFB is a murine renal interstitial ﬁbroblast cell line originally
isolated from SJL mouse kidney and was a generous gift from Eric G.
Neilson. These cells have been extensively characterized, and they
express the ﬁbroblast speciﬁc protein (FSP-1) [14,30]. Murine embry-
onic ﬁbroblasts (MEFs) were isolated from mice embryos at 10 days
post-coitum. Embryos were treated for 30 min with 0.25% EDTA–
trypsin (Gibco-BRL, Cheshire, UK) and mechanically homogenized.
Before digestion, the top of the head (eye and above) and visible
innards were removed. The rest of the embryonic tissue is basically
ﬁbroblasts at this stage of the embryo development. Immortalized
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genotyped by PCR analysis. MEF cells from Fn14−/− or wild type
mice were used as primary culture within the ﬁrst 5 passages. For
cell culture media and reagents see the Supplementary material.
Cell viability was quantiﬁed by the PMS/MTS test in TFBs [31] and
by the crystal violet assay in MEFs [32], and apoptosis was quantiﬁed
by ﬂow cytometry assessment of DNA content of 10,000 cells [33] and
characterized by morphology [34]. Protein expression was assessed
by ﬂow cytometry [35] in the case of cell surface Fn14 (as detailed
in the Supplementary information) and by Western blot and immu-
nostaining for other proteins. Expression of mRNA was quantiﬁed
by real time reverse transcription-polymerase chain reaction [36].
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2.2. Animal models
Studies were conducted according with the NIH Guide for the Care
and Use of Laboratory Animals. TWEAK KO or wild type (WT) C57BL/6
mice provided by Biogen Idec [22,38], (12- to 14-week-old) were
anesthetized and the left ureter was ligated (n = 9/group) or
manipulated without ligation (Sham, n = 5/group). Peri-operative
analgesic was administered to the mice. Animals were sacriﬁced
48 h, 7, 14 or 21 days after surgery. Kidneys were perfused in situ
with cold saline before removal. Half a kidney was snap-frozen in0 
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ﬁxed and parafﬁn-embedded for histological studies.
Tubular cell death is an early event in UUO, observed from day 1
[39] and was assessed by TUNEL (Supplementary material). Inﬂam-
matory mediators like chemokines increase from day 1 up to 7–10 days
from obstruction and are followed by inﬂammatory cell inﬁltration
[40–43]. Inﬂammation and ﬁbrosis were assessed on days 2 through
21 after ureteral obstruction. Histological studies and ELISA and WB
from tissue lysates are detailed in the Supplementary material.
Adenoviral vector expressing soluble TWEAK or control vector
expressing green ﬂuorescence protein (GFP) was generated and
delivered intravenously as previously described [44]. Vectors were
injected in mice without underlying kidney injury. Kidney histology
was assessed 7 and 20 days later.
2.3. Statistics
Statistical analysis was performed using SPSS software (SPSS Inc.,
Chicago, IL). A non-parametric test (U Mann–Whitney) was used for
the analysis of statistic differences between the groups. A p value b0.05
was considered signiﬁcant. Results are expressed as mean ± SEM.
3. Results
3.1. Increased kidney Fn14 in experimental UUO
WTand TWEAKKOmicewere sacriﬁced at days 2, 7, 14, and 21 after
UUO. Fn14 (Fig. 1A) and TWEAK (Fig. 1B) gene expressions were
upregulated in obstructed kidneys (Fig. 1B). An increased expression
of the receptor that sensitizes to TWEAK actions is the main regulator
of the activity of the TWEAK/Fn14 system [16]. Increased Fn14 protein
was conﬁrmed in obstructed kidneys by Western blot (Fig. 1C).
3.2. Renal cell apoptosis and interstitial inﬂammation are delayed in
mice lacking TWEAK
The ﬁrst stages of UUO are characterized by tubular programmed
cell death and tubulointerstitial inﬂammation [39,45]. In the early
stages of UUO, histological tubular injury score (Fig. 2A) and TUNEL
(Fig. 2B) positive tubular cells were lower in TWEAK KO than in WT
kidneys. Kidney macrophage chemoattractant protein (MCP-1) and
RANTES mRNA upregulation was delayed in UUO kidneys from
TWEAK KO as compared to WT mice (Supplementary Fig. S1A). This
was associated with lower protein levels as exempliﬁed by lower kid-
ney MCP-1 in TWEAK KO obstructed kidneys at both days 7 and 14
(Supplementary Fig. S1B). MCP-1 and RANTES recruit macrophages
and T cells [21]. Immunohistochemistry showed less interstitial F4/80
macrophages and CD3 lymphocytes in UUO TWEAK KO kidneys than
in WT kidneys (Fig. 3A and B). In the case of CD3, this reduction was
observed up to 14 days after obstruction.
3.3. Renal myoﬁbroblast accumulation is delayed in TWEAK KO mice
with UUO
The number of myoﬁbroblasts expressing alpha-smooth muscle
actin (αSMA) was lower in TWEAK KO than inWT obstructed kidneys
at days 7 and 21 after obstruction (Fig. 4). In addition, the number of
proliferating αSMA positive myoﬁbroblasts was lower in TWEAK KOFig. 6. Overexpression of TWEAK in mice without prior underlying kidney disease. DNA fragm
tubular damage marker KIM-1 (B), the macrophage marker F4/80 (C), the T lymphocyte mar
tiﬁed in 6 ﬁelds) (E), Sirius red staining (F) and Masson's trichrome staining (MTS) (G) of
overexpressing TWEAK (Adeno-TWEAK). Magniﬁcation ×100, scale bar 200 μm, exce
overexpression induces a time-dependent increment of tubular damage (and cell death
#p b 0.05 vs. Adeno-TWEAK 7 day.as compared to WT obstructed kidneys at day 7 (Fig. 4). However,
by day 14 the differences between TWEAK KO and WT obstructed
kidneys were attenuated, suggesting that the lack of TWEAK delays
the accumulation of myoﬁbroblasts. TWEAK may modulate a ﬁrst
batch of myoﬁbroblast proliferation, while Fn14 and TWEAK expres-
sions are high, but at 21 days the reduced myoﬁbroblast numbers in
TWEAK−/− mice could reﬂect the reduced kidney damage. That
may explain why the difference in αSMA positive cells observed at
21 days after obstruction in TWEAK KO mice kidneys is not reﬂected
in double αSMA and PCNA positive cells at the same time point.
3.4. Reduced ECM deposition in TWEAK KO mice with UUO
Consistent with the reduced number of αSMA positive cells in
TWEAK KO as compared to WT obstructed kidneys 7 days after
UUO, collagen type I and ﬁbronectin (FN) mRNA were signiﬁcantly
reduced in TWEAK KO vs. WT obstructed kidneys at this time point,
and FN mRNA expression in TWEAK KO kidneys lagged behind that
in WT mice (Supplementary Fig. S2). However, although Sirius
red-stained interstitial ECM was signiﬁcantly increased at day 7 in
UUO kidneys, no signiﬁcant differences between WT and TWEAK KO
mice were observed. A trend towards lower interstitial ECM deposi-
tion was observed in TWEAK KO kidney by day 14, which was statis-
tically signiﬁcant after 21 days of obstruction (Fig. 5). These results
indicate that TWEAK contributes to late-stage ECM accumulation in
the progression of kidney ﬁbrosis.
3.5. Overexpression of TWEAK induces structural damage, inﬂammation
and ECM deposition in mouse kidney
TWEAK was overexpressed in mice by infection with an adenovi-
ral vector encoding TWEAK (Adeno-TWEAK), resulting in increased
circulating TWEAK levels, as shown previously [44]. For comparison,
mice were infected with a control adenoviral vector (Adeno-GFP).
Seven and 20 days following adenoviral infection a complete analysis
was performed of tubular cell death, inﬂammatory inﬁltrates and
ﬁbrotic scar. TUNEL (Fig. 6A) staining and kidney injury molecule 1
(KIM-1) immunodetection (Fig. 6B) was performed to study the
tubular damage, which was increased in TWEAK overexpressing
mice. Increase DNA fragmentation was observed at 7 and 20 days
after adenovirus infection, and tubular KIM-1 expression increased
signiﬁcantly at 20 days. TWEAK overexpression was also associated
to an increased kidney inﬁltration by F4/80 macrophages (Fig. 6C)
and CD3 lymphocytes (Fig. 6D). CD3 population increased earlier
than F4/80 cells, as observed in the UUO model. Kidneys from mice
overexpressing TWEAK showed more myoﬁbroblasts and proliferat-
ing myoﬁbroblasts than control mice kidneys, 7 and 20 days after
adenovirus injection (Fig. 6E), along with an increase of interstitial
cortex ECM deposition at 20 days (assessed by Masson's trichrome
and Sirius red stainings) (Fig. 6F and G).
At 20 days after infection, ﬁbrotic areas colocalized with KIM-1
and F4/80 immunostainings in mice overexpressing TWEAK (Supple-
mentary Fig. S3).
3.6. TWEAK promotes cultured renal ﬁbroblast proliferation
We studied the biological actions of TWEAK on cultured murine
renal interstitial ﬁbroblasts that express αSMA. These renal interstitialentation (assessed by TUNEL and quantiﬁed in 10 ﬁelds) (A), immunodetection of the
ker CD3 (D), the myoﬁbroblasts marker αSMA and its colocalization with PCNA (quan-
kidneys from mice infected with an adenovirus control (Adeno-GFP) or an adenovirus
pt for the immunoﬂuorescence (magniﬁcation ×200, scale bar 100 μm). TWEAK
), inﬂammatory inﬁltration and ECM accumulation. *p b 0.05 vs. Adeno-GFP control.
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1750 A.C. Ucero et al. / Biochimica et Biophysica Acta 1832 (2013) 1744–1755ﬁbroblasts expressed Fn14 mRNA (qRT-PCR, not shown) and protein.
Fn14 was immunodetected in the lysates (Western blot) and on the
surface of the TFB cells (ﬂow cytometry) (Supplementary Fig. S4A).
In serum-deprived cultures, TWEAK dose-dependently increased
the number of viable ﬁbroblasts (Fig. 7A). The effect persisted for up
to 72 h. An increased number of viable cells may be the result of in-
creased mitosis or decreased cell death. The main effect of TWEAK
was to increase the proportion of dividing cells (Fig. 7B). Nuclear
morphology conﬁrmed an increased number of cells undergoing
mitosis among cells treated with TWEAK (Supplementary Fig. S4B).
Flow cytometry of DNA content also showed a mild antiapoptotic
effect of TWEAK (Supplementary Fig. S4C).
3.7. The Ras/ERK pathway mediates TWEAK-induced ﬁbroblast
proliferation
Ras GTPases have been recently related to renal ﬁbrosis [4,46].
There is no information concerning the signaling pathways activated
by TWEAK/Fn14 in renal ﬁbroblasts. In renal tubular cells TWEAK
activates mitogen activated protein kinases (MAPKs) such as the
extracellular-regulated kinase (ERK) and p38 [22]. While Ras hasnot been previously related to TWEAK/Fn14 signaling, MEK/ERK is ac-
tivated downstream of Ras in different cell systems [47,48].
The ERK inhibitor PD98059 prevented TWEAK-induced prolifera-
tion in renal ﬁbroblasts (Fig. 7C). Cyclin D1 regulates the transition
from the G1/G0 phase (quiescence) to the S phase (synthesis) in cell
cycle progression. TWEAK increased cyclin D1 protein expression
after 8 h of stimulation, which correlated with the increase in prolif-
eration observed at 24 h. TWEAK-induced cyclin D1 expression
was prevented by PD98059, indicating ERK activation dependency
(Supplementary Fig. S5A). By contrast, the p38 inhibitor SB203580
did not prevent TWEAK-induced proliferation (Fig. 7C). TWEAK acti-
vation of NFκB has been implicated in cardiac ﬁbroblast proliferation
[49]. However, neither parthenolide nor BAY11-7082, both of them
NFκB inhibitors, prevented TWEAK-induced renal ﬁbroblast prolifera-
tion (Supplementary Fig. S5B).
In renal ﬁbroblasts TWEAK activated Ras within 1 min of stimulation
(Fig. 7D). This fast activation of Ras GTPases by TWEAK is consistentwith
the known biology of the Ras system. In order to conﬁrm the receptor
speciﬁcity of this novel TWEAK action, we compared primary cultured
MEF cells from Fn14−/− mice to MEF cells from wild type mice, which
express Fn14 (Supplementary Fig. S5C). TWEAK activated Ras in wild
1751A.C. Ucero et al. / Biochimica et Biophysica Acta 1832 (2013) 1744–1755type MEF cells after 1 min of TWEAK stimulation but not in MEF cells
lacking Fn14 (Supplementary Fig. S5C). Activation (phosphorylation) of
ERK was observed after 15 min and 24 h of TWEAK stimulation. Activa-
tion of ERK 1/2 was blocked by pretreatment with farnesylthiosalicylic
acid (FTS), a Ras inhibitor (Supplementary Fig. S5D). These results
provide the ﬁrst evidence of a TWEAK/Ras relationship.
Preincubationwith the Ras inhibitor FTS prevented TWEAK-induced
proliferation in renal ﬁbroblasts (Fig. 7E). To further explore the role
of Ras in TWEAK-induced ﬁbroblast proliferation, mouse embryonic
ﬁbroblasts (MEFs) deﬁcient in two Ras isoforms, N-Ras and H-Ras
(NH Ras−/−:N-ras−/−/H-ras−/−) were studied. N-ras+/− and H-ras+/−
MEFs (NH Ras+/−) were used as controls because they express
completely functional Ras isoforms [46]. Contrary to control MEFs, cell
viability was not increased in MEFs lacking Ras in response to TWEAK
stimulation for 24 h (Fig. 7F).
These observations support the involvement of Ras/ERK in
TWEAK-induced ﬁbroblast proliferation.A 
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Fig. 8. ECM protein levels in cultured ﬁbroblasts after TWEAK stimulation. A–C)
TWEAK reduces cell-associated collagen type I and both cell-associated and secreted ﬁ-
bronectin in NH Ras+/−MEFs, but not in NH Ras−/−MEFs. Representative pictures (A)
and quantiﬁcation (B, C) of Western blots of precursor (180 kD) and mature (80 kD)
collagen type I (B) and of ﬁbronectin (C) from lysates and supernatants of MEFs stim-
ulated with TWEAK for 72 h. *p b 0.05 vs. control.3.8. TWEAK reduces collagen type I and FN protein levels in cultured
renal ﬁbroblasts and MEFs
In addition to promoting renal ﬁbroblast proliferation in vitro,
TWEAK decreased collagen type I and FN proteins following 72 h
incubation in TFB cells and MEFs (Fig. 8 and Supplementary Fig. S6).
In MEFs, TWEAK decreased cell-associated collagen type I (Fig. 8B),
and cell-associated and supernatant ﬁbronectin (Fig. 8C). By contrast,
TWEAK failed to decrease ECM proteins in MEFs lacking N- and H-Ras
isoforms (Fig. 8A to C).
In TFB cells TWEAK decreased cell-associated and secreted type I
collagen and FN proteins (Supplementary Fig. S6). TWEAK induces
p38 phosphorylation at 15 min and 24 h in TFB cells, and this was
again blocked by preincubation with FTS (Supplementary Fig. S6A).
The p38 inhibitor SB203580 prevented the TWEAK-induced reduction
in collagen type I and FN proteins, suggesting the involvement of
MAPK p38 (Supplementary Fig. S6B to D). These results support a role
for Ras and p38 in the regulation of ECM production in response to
TWEAK.MAPK p38 has been previously related to Ras signaling [50,51].
3.9. TWEAK activates NFκB in renal ﬁbroblasts
TWEAK is a proinﬂammatory cytokine in tubular cells [21]. In renal
ﬁbroblasts TWEAK induced NFκB RelA/p65 translocation to the nucleus
(Fig. 9A) and nuclear NFκB DNA binding activity (Fig. 9B). TWEAK also
increased MCP-1 and RANTES mRNA (Fig. 9C). Parthenolide, an
inhibitor of NFκB, prevented NFκB activation and chemokine mRNA
expression (Fig. 9A to C). This suggests that TWEAK may contribute to
renal inﬂammation through direct effects on both proximal tubular
cells [21] and renal interstitial ﬁbroblasts.
4. Discussion
The main ﬁnding of this study is that TWEAK deﬁciency delays the
accumulation of myoﬁbroblasts and results in reduced interstitial ﬁ-
brosis in a model of persistent kidney insult, UUO. In addition, chronic
TWEAK overexpression induces interstitial ﬁbrosis in mice without
prior underlying kidney injury. TWEAK actions on renal ﬁbroblasts
may contribute to the in vivo observations, as TWEAK promotes in-
ﬂammatory activity and proliferation in renal ﬁbroblast cultures.
TWEAK also downregulates ECM proteins in cultured renal ﬁbroblasts
and this may contribute to the delayed, rather than early, decreased
ECM deposition in vivo. Furthermore, we also report for the ﬁrst
time the involvement of Ras GTPases in TWEAK signaling.
The demonstration that chronic TWEAK overexpression promotes
renal ﬁbrosis in mice without underlying kidney injury and that
TWEAK deﬁciency decreases renal ﬁbrosis in the UUOmodel supports
a key role for TWEAK in kidney ﬁbrosis. In this regard, in the UUO
model the obstruction is not released. Thus, protection from ﬁbrosis
in TWEAK deﬁcient mice was observed despite the continuous pres-
ence of the stimulus for renal ﬁbrosis. This assessment of both the
chronic effects of TWEAK on kidney ﬁbrosis as well as of the effects
of TWEAK deﬁciency on a chronic persistent kidney injury model is
a key point of the study. These results may be relevant in many
human kidney diseases where the kidney insult is persistent.
Dissociation between protection from tubular injury/inﬂammation
and protection from ﬁbrosis has been observed in the UUO model
when targeting pro-inﬂammatory molecules, illustrating the complex
relationship between inﬂammation and ﬁbrosis. Toll-like receptor-2
(TLR2) deﬁciency decreases tubular apoptosis, inﬂammation and the
activated ﬁbroblast population following UUO [52]. However, TLR2
absence did not modify ECM deposition in obstructed kidneys. Tumor
necrosis factor-alpha (TNFα) targeting decreased early apoptosis,
inﬂammation and interstitial volume, but there was no signiﬁcant dif-
ference in the extent of renal ﬁbrosis after UUO [53–56]. TNFα repres-
sion of collagen type I gene transcription, as observed in human
1752 A.C. Ucero et al. / Biochimica et Biophysica Acta 1832 (2013) 1744–1755dermal ﬁbroblasts [57], may prevent further reduction of ﬁbrosis when
TNFα is targeted. By contrast, despite a direct suppressive effect on ECM
production in cultured ﬁbroblasts, TWEAK promoted ﬁbroblastB 
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in vivo in UUO was to decrease renal ﬁbrosis.
Our study in the UUOmodel also provides novel perspective on the
contribution of upregulated TWEAK, as well as Fn14, to chronic pathol-
ogy. In prior studies of AKI, Fn14 gene expression is increased out of
proportion compared to TWEAK expression, raising the potential for
Fn14 self-oligomerization and activation. Nonetheless, TWEAK
targeting protected from AKI induced by folic acid [19,21] and Fn14
targeting protected from acute injury induced by transient kidney
ischemia–reperfusion [19]. Not unexpectedly, given the transient
nature of the kidney insult, protection by Fn14 targeting at the time of
the transient ischemia–reperfusion period was followed, when perfu-
sion was restored, by decreased residual renal ﬁbrosis. However, these
studies did not address whether TWEAK overexpression may promote
renal ﬁbrosis, whether TWEAK deﬁciency might protect from renal ﬁ-
brosis, whether protection from renal ﬁbrosis might be observed in
the presence of a persistent kidney insult or whether TWEAK has direct
actions on renal ﬁbroblasts. Our study provides novel information on all
these four aspects. Of particular interest, this is the ﬁrst time that the
kidney effects of endogenous TWEAK overexpression have been stud-
ied. TWEAK overexpressionwas enoughby itself to trigger kidney ﬁbro-
sis in mice without underlying kidney disease. Current thinking is that
the upregulation of Fn14 expression during kidney injury is a key factor
in sensitizing the kidneys to the deleterious effects of constitutively
expressed TWEAK. However, these experiments show that a primary
increase in TWEAK expression may also result in kidney injury and ﬁ-
brosis. This ﬁnding suggests the pathological relevance of increased
levels of kidney TWEAK found in experimental models and leukocyte,
kidney and urinary TWEAK found in clinical kidney injury [21,27,28].
Speciﬁcally, increased urinary TWEAK is correlated with the renal dis-
ease activity of lupus nephritis, a condition known to evolve to kidney
ﬁbrosis if untreated [28].
Renal ﬁbrosis is characterized by an increased myoﬁbroblast num-
ber, which leads to excessive ECM deposition [58]. Ras-dependent
activation of ERK and the role of Ras in ﬁbroblast proliferation are
well established [4,59,60]. Indeed, myoﬁbroblast activation and
renal ﬁbrosis following UUO are decreased when H-Ras is deleted
[1]. Furthermore epigenetic modiﬁcations that silence the Ras inhibi-
tor RASAL1 perpetuate ﬁbroblast activation and ﬁbroblast prolifera-
tion [4]. However, TWEAK activation of Ras or induction of renal
ﬁbroblast proliferation has not been previously described. In this
regard, TWEAK induced renal and embryonic ﬁbroblast proliferation
through Ras/ERK signaling. In accordance with this in vitro observa-
tion, the absence of TWEAK was associated with a reduced kidney
myoﬁbroblast population following UUO. TGF-β1-induced MEF pro-
liferation also requires N- and H-Ras isoforms and ERK pathway
recruitment [59]. Since TGF-β1 can induce Fn14 expression in ﬁbro-
blasts [61,62], these pathways might cooperate to promote prolifera-
tion of ﬁbroblasts.
The end-result of ﬁbroblast activation and proliferation is ECM
deposition and ﬁbrosis. Since TWEAK deﬁciency decreased early
tubular cell loss, and delayed interstitial inﬂammation andmyoﬁbroblast
population after UUO, a decrease in ECM deposition was also expected atFig. 9. TWEAK activates the NFκB canonical pathway in renal ﬁbroblasts. A) TWEAK
promotes the nuclear translocation of NFκB subunit p65/RelA, as assessed by immuno-
ﬂuorescence. This is prevented by parthenolide, a NFκB inhibitor. PI corresponds to
propidium iodide. Confocal microscope magniﬁcation ×400, scale bar 50 μm. B)
TWEAK stimulation for 30 min promotes NFκB binding to DNA consensus motifs in
kidney interstitial ﬁbroblasts, assessed by electrophoretic mobility shift assay (EMSA)
of nuclear extracts. This is also inhibited by parthenolide. *p b 0.05 vs. control.
#p b 0.05 vs. TWEAK-treated. C) TWEAK upregulates MCP-1 and RANTES gene expres-
sions at 3 and 8 h in kidney interstitial ﬁbroblasts. Pretreatment with parthenolide in-
hibits this effect indicating NFκB dependence. *p b 0.05 vs. control. #p b 0.05 vs.
TWEAK-treated.
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observed at day 7. As renal ﬁbrosis increased from 5 to 10% of the
tubulointerstitial area at day 7 to about 25% at days 14–21 in WT mice,
a reduced ECM deposition was eventually observed in TWEAK KO.
Based on the cell culture data, we hypothesize that the effect of TWEAK
deﬁciency on ECM deposition reﬂects the balance of TWEAK actions in
promoting renal ﬁbroblast expansion and limiting ECM expression.
Since TWEAK promotes the proliferation and decreases ECM proteins in
cultured renal ﬁbroblasts, the reduction in ﬁbrosis in TWEAK deﬁcient
micemay be delayed by a loss of TWEAK direct effects on ECM. However,
importantly, the net effect is reduced late-stage ﬁbrosis. The effects of
TWEAK on renal ﬁbroblasts mirror its effects on other mesenchymal cell
types. Thus, TWEAK promotes cell proliferation and inhibits differentia-
tion [17]. Importantly, similar results were obtained with cultured renal
ﬁbroblasts and MEFs and in both cell types TWEAK effects were N- and
H-Ras-dependent. N- and H-Ras are also negative intracellular regulators
of ECM synthesis in response to TGFβ1 in MEFs [59]. Fig. 10 shows a
model reﬂecting the potential dual role of Ras in promoting ﬁbroblast
proliferation and inhibiting ECM production [59], integrated with our
results demonstrating TWEAK-induced changes in ﬁbroblast biologyme-
diated by theRas pathway thatmay impact on kidneyﬁbrosis. In addition,
TWEAK may have proﬁbrotic actions on other renal cell types, such as
tubular cells, not shown in the ﬁgure [16].
In addition to ﬁbrosis TWEAK also regulated tubular injury and
inﬂammation in the UUO model. Loss of tubular cells (tubular atro-
phy) often through tubular apoptosis is a key process in CKD progres-
sion [63]. TWEAK cooperates with other inﬂammatory cytokines to
induce tubular cell apoptosis [19–22]. Tubular cell apoptosis is also
an early feature of UUO [64,65]. In this regard, TUNEL + dead tubularFn14 
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Fig. 10. TWEAK regulation of ﬁbrosis-related pathways in kidney ﬁbroblasts. Only ac-
tions of TWEAK on kidney ﬁbroblasts are represented, although TWEAK may also elicit
responses in tubular cells potentially contributing to ﬁbrosis such as cell injury and
death and inﬂammatory responses [16]. TWEAK activates intracellular signaling cas-
cades that may modulate ﬁbroblast biology and impact on kidney ﬁbrosis. Thus,
TWEAK activates Ras and Ras-mediated p38 and ERK phosphorylations. ERK activation
promotes ﬁbroblast proliferation while p38 activation decreases ECM protein levels. In
addition, TWEAK activates NFκB and expression of chemokines in renal ﬁbroblasts.
However, TWEAK does not require NFκB activation to promote mitogenesis in kidney
ﬁbroblasts. TWEAK also has actions on tubular epithelial cells, not shown in the ﬁgure.
Some of these actions, such as induction of tubular cell death in an inﬂammatory con-
text, do not always match actions of TWEAK observed in kidney ﬁbroblasts. However,
both TWEAK-induced ﬁbroblast proliferation and TWEAK-induced tubular cell apopto-
sis may contribute to progression of kidney disease.cells were more common in WT type than in TWEAK KO UUO kid-
neys. TWEAK also regulates renal inﬂammation in toxic or ischemic
AKI [19,21,22,66]. Our results indicate that TWEAK also promotes
renal interstitial inﬂammation after UUO in mice. Renal ﬁbroblasts
express chemokines [67]. TWEAK induced NFκB activation and che-
mokine secretion in renal ﬁbroblasts. TWEAK contribution to intersti-
tial inﬂammation in UUO might thus be mediated through NFκB
signaling and chemokine secretion in renal tubular cells and ﬁbro-
blasts. Indeed, NFκB is a key mediator of renal inﬂammation [68]
and NFκB targeting decreased inﬂammatory cytokines and ECM pro-
teins in murine UUO [69]. In addition, therapeutic targeting of CCR2,
the MCP-1 receptor, reduced macrophage inﬁltration and interstitial
ﬁbrosis following UUO in mice [70].5. Conclusions
TWEAK has Ras-dependent pro-proliferative and NFκB-dependent
proinﬂammatory actions on kidney ﬁbroblasts and TWEAK deﬁciency
is associated with delayed accumulation of myoﬁbroblasts and reduced
late stage ECM deposition in an experimental model of persistent
kidney injury. Furthermore, overexpression of TWEAK in the absence
of underlying kidney disease resulted in kidney ﬁbrosis. Potential anti-
ﬁbrotic actions of TWEAK targeting on human kidney disease where
the kidney insult is persistent should be explored.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.05.032.Acknowledgements
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